查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606308

癌症微生物组定序市场：按产品、技术、应用和最终用户划分 - 2025-2030 年全球预测

Cancer Microbiome Sequencing Market by Product (Kits & Assays, Service, Software), Technology (Next-Generation Sequencing, Polymerase Chain Reaction), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症微生物组定序市值为17.4亿美元，预计到2024年将达到18.4亿美元，复合年增长率为5.79%，到2030年将达到25.9亿美元。

癌症微生物组定序的范围包括分析癌症患者体内的微生物群落，以了解它们对癌症发生、进展和治疗反应的影响。这个不断发展的领域至关重要，因为微生物组在调节免疫反应和药物疗效中的作用越来越受到人们的认可，使其成为个人化医疗策略不可或缺的一部分。癌症微生物组定序的应用涵盖肿瘤学研究、治疗开发和诊断平台。它提供了对与不同癌症类型相关的微生物变化的深入了解，并可能产生新的生物标记和治疗标靶。最终用途范围包括学术机构、生物技术公司和医疗保健提供者，希望将微生物组见解转化为临床实践。

主要市场统计
基准年[2023] 17.4亿美元
预计年份 [2024] 18.4亿美元
预测年份 [2030] 25.9亿美元
复合年增长率（%） 5.79%

影响该市场的主要成长要素包括定序技术的进步、癌症研究投资的增加以及对微生物相关健康影响的认识不断提高。开发以微生物为基础的疗法、伴同性诊断和精准医学方法的时机已经成熟。公司可以透过与研究机构合作并利用人工智慧来了解复杂的微生物与癌症相互作用而受益。然而，市场面临全面微生物定序高成本、资料标准化挑战以及需要强有力的法规结构等限制。微生物与癌症相互作用的复杂性和缺乏临床共识给临床传播带来了重大挑战。

业务成长的创新领域包括开发非侵入性诊断工具、整合微生物组资料和基因组学以进行全面的癌症分析，以及针对特定癌症相关微生物群的新疗法，例如生物製剂。市场的本质是高度动态的，由快速的技术进步和跨学科合作所驱动。公司应专注于针对利基癌症和微生物物种的研究，以及扩充性的、特异性患者的解决方案。为了利用潜在的商机，策略性倡议包括促进与学术界的合作、投资跨学科团队以及倡导监管透明度。

市场动态：揭示快速发展的癌症微生物组定序市场的关键市场洞察

供需的动态交互作用正在改变癌症微生物组定序市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症患者数量增加
    • 政府促进癌症预防、诊断和治疗的倡议
    • 研究活动增加，人们对肠道微生物组重要性的认识不断提高
  • 市场限制因素
    • 使用定序服务成本高且缺乏熟练人员
  • 市场机会
    • 次世代定序仪的进展
    • 利用人工智慧、机器学习和生物资讯学实现癌症检测
  • 市场挑战
    • 与资料分析相关的技术限制和困难

波特五力：驾驭癌症微生物定序市场的策略工具

波特的五力框架是了解癌症微生物组定序市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症微生物组定序市场的外部影响

外部宏观环境因素在塑造癌症微生物组定序市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解癌症微生物组定序市场的竞争格局

对癌症微生物组定序市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症微生物组定序市场供应商的绩效评估

FPNV定位矩阵是评估癌症微生物组定序市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了癌症微生物组定序市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，癌症微生物组定序市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症患者数量不断增加
      • 政府促进癌症预防、诊断和治疗的倡议
      • 研究活动增加，人们对肠道微生物组重要性的认识不断提高
    • 抑制因素
      • 使用定序服务的成本较高，且技术人员短缺。
    • 机会
      • 次世代定序的进展
      • 利用人工智慧、机器学习和生物资讯学实现癌症检测
    • 任务
      • 与资料分析相关的技术限制和困难
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症微生物组定序市场：副产品

  • 套件和检测
  • 服务
  • 软体

第七章癌症微生物组定序市场：依技术分类

  • 次世代定序
  • 聚合酵素链锁反应

第八章癌症微生物组定序市场：依应用分类

  • 诊断
  • 转化研究

第 9 章癌症微生物组定序市场：依最终用户分类

  • 学术研究所
  • 医院和诊断实验室
  • 製药和生物技术公司

第十章美洲癌症微生物组定序市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太癌症微生物组定序市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的癌症微生物组定序市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Athos Therapeutics Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb
  • CosmosID
  • Creative Biolabs
  • Evelo Biosciences
  • EzBiome
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals
  • Illumina, Inc.
  • LC Sciences
  • Merck KGaA
  • Metagen Therapeutics
  • MV BioTherapeutics SA
  • Norgen Biotek Corp.
  • Novogene Co, Ltd.
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Vedanta Biosciences.
  • Viome Life Sciences, Inc.
Product Code: MRR-5C6F41F5AF92

The Cancer Microbiome Sequencing Market was valued at USD 1.74 billion in 2023, expected to reach USD 1.84 billion in 2024, and is projected to grow at a CAGR of 5.79%, to USD 2.59 billion by 2030.

The scope of cancer microbiome sequencing encompasses the analysis of microbial communities within cancer patients to understand their impact on cancer development, progression, and treatment response. This growing field is vital due to the increasing recognition of the microbiome's role in modulating immune responses and drug efficacy, making it an essential component of personalized medicine strategies. The application of cancer microbiome sequencing spans oncology research, therapeutic development, and diagnostic platforms. It offers insights into the microbial alterations associated with different cancer types, potentially leading to novel biomarkers and therapeutic targets. The end-use scope involves academic institutions, biotechnology companies, and healthcare providers looking to integrate microbiome insights into clinical practice.

KEY MARKET STATISTICS
Base Year [2023] USD 1.74 billion
Estimated Year [2024] USD 1.84 billion
Forecast Year [2030] USD 2.59 billion
CAGR (%) 5.79%

Key growth factors influencing this market include advancements in sequencing technologies, rising investments in cancer research, and heightened awareness of microbiome-related health implications. Opportunities are ripe in developing microbial-based therapeutics, companion diagnostics, and precision medicine approaches. Companies can benefit from partnerships with research institutions and leveraging AI to elucidate complex microbiome-cancer interactions. However, the market faces limitations such as high costs of comprehensive microbial sequencing, challenges in data standardization, and the need for robust regulatory frameworks. The complexity of microbiome-cancer interactions and the current lack of clinical consensus pose significant challenges to widespread clinical adoption.

Innovative areas for business growth include the development of non-invasive diagnostic tools, integration of microbiome data with genomics for comprehensive cancer profiling, and novel probiotic formulations targeting specific cancer-related microbiota. The nature of the market is highly dynamic, driven by rapid technological advancements and cross-disciplinary collaborations. Businesses should focus on targeted research in niche cancer types or microbial species, alongside scalable patient-specific solutions. To capitalize on the potential opportunities, fostering collaborations with academia, investing in cross-disciplinary teams, and advocating for increased regulatory clarity are recommended strategic moves.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Microbiome Sequencing Market

The Cancer Microbiome Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of cancer cases across the world
    • Government initiatives to promote cancer prevention, diagnosis, and care
    • Growing number of research activities and increasing awareness about the significance of gut microbiome
  • Market Restraints
    • High cost of availing sequencing services and lack of skilled personnel
  • Market Opportunities
    • Advancements in next-generation sequencing
    • Utilization of AI, ML, and bioinformatics to enable cancer detection
  • Market Challenges
    • Technical limitations and difficulties associated with data analysis

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Microbiome Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Microbiome Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Microbiome Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Microbiome Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Microbiome Sequencing Market

A detailed market share analysis in the Cancer Microbiome Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Microbiome Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Microbiome Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Microbiome Sequencing Market

A strategic analysis of the Cancer Microbiome Sequencing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Microbiome Sequencing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Athos Therapeutics Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb, CosmosID, Creative Biolabs, Evelo Biosciences, EzBiome, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals, Illumina, Inc., LC Sciences, Merck KGaA, Metagen Therapeutics, MV BioTherapeutics SA, Norgen Biotek Corp., Novogene Co, Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Vedanta Biosciences., and Viome Life Sciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Microbiome Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Kits & Assays, Service, and Software.
  • Based on Technology, market is studied across Next-Generation Sequencing and Polymerase Chain Reaction.
  • Based on Application, market is studied across Diagnostics and Translational Research.
  • Based on End User, market is studied across Academic & Research Institutes, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of cancer cases across the world
      • 5.1.1.2. Government initiatives to promote cancer prevention, diagnosis, and care
      • 5.1.1.3. Growing number of research activities and increasing awareness about the significance of gut microbiome
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of availing sequencing services and lack of skilled personnel
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in next-generation sequencing
      • 5.1.3.2. Utilization of AI, ML, and bioinformatics to enable cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations and difficulties associated with data analysis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Microbiome Sequencing Market, by Product

  • 6.1. Introduction
  • 6.2. Kits & Assays
  • 6.3. Service
  • 6.4. Software

7. Cancer Microbiome Sequencing Market, by Technology

  • 7.1. Introduction
  • 7.2. Next-Generation Sequencing
  • 7.3. Polymerase Chain Reaction

8. Cancer Microbiome Sequencing Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostics
  • 8.3. Translational Research

9. Cancer Microbiome Sequencing Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Hospitals & Diagnostic Laboratories
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Cancer Microbiome Sequencing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Microbiome Sequencing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Microbiome Sequencing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. AstraZeneca PLC
  • 4. Athos Therapeutics Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Bristol-Myers Squibb
  • 7. CosmosID
  • 8. Creative Biolabs
  • 9. Evelo Biosciences
  • 10. EzBiome
  • 11. F. Hoffmann-La Roche AG
  • 12. Ferring Pharmaceuticals
  • 13. Illumina, Inc.
  • 14. LC Sciences
  • 15. Merck KGaA
  • 16. Metagen Therapeutics
  • 17. MV BioTherapeutics SA
  • 18. Norgen Biotek Corp.
  • 19. Novogene Co, Ltd.
  • 20. Qiagen NV
  • 21. Thermo Fisher Scientific Inc.
  • 22. Vedanta Biosciences.
  • 23. Viome Life Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER MICROBIOME SEQUENCING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER MICROBIOME SEQUENCING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER MICROBIOME SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER MICROBIOME SEQUENCING MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SERVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023